MaxCyte (MXCT) director receives RSU and stock option grant

Rhea-AI Filing Summary

MAXCYTE, INC. director Yasir B. Al-Wakeel received equity awards as part of his annual non-employee director compensation. He was granted 30,421 shares of Common Stock in the form of restricted stock units, plus stock options for 49,579 shares at an exercise price of $1.13 per share.

The RSUs and option grant were made under the company’s Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, contingent on his continued service. Following the RSU grant, he directly owns 80,998 shares of Common Stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Al-Wakeel Yasir B.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	49,579	$0.00	--
Grant/Award	Common Stock	30,421	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 49,579 shares (Direct, null); Common Stock — 80,998 shares (Direct, null)

Footnotes (1)

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Key Figures

RSU grant: 30,421 shares Option grant size: 49,579 options Option exercise price: $1.13 per share +3 more

6 metrics

RSU grant 30,421 shares Restricted stock units representing Common Stock

Option grant size 49,579 options Stock options over Common Stock

Option exercise price $1.13 per share Conversion/exercise price for 49,579 options

Shares held after RSU grant 80,998 shares Direct Common Stock ownership following RSU grant

Vesting date June 17, 2027 Vesting of shares underlying annual director grant

Option expiration June 16, 2036 Expiration date of stock options granted

Key Terms

restricted stock units ("RSUs"), Equity Grant Policy, non-employee directors, vesting

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Equity Grant Policy financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

non-employee directors financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

vesting financial

"The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Al-Wakeel Yasir B.

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A		30,421(1)(2)	A	$0	80,998	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.13	06/17/2026		A		49,579		(2)	06/16/2036	Common Stock	49,579	$0	49,579	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

	/s/ Maher Masoud, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did MaxCyte (MXCT) director Yasir B. Al-Wakeel receive?

Yasir B. Al-Wakeel received 30,421 restricted stock units and stock options for 49,579 shares of MaxCyte Common Stock. These awards represent annual compensation under the company’s Equity Grant Policy for non-employee directors, rather than open-market share purchases.

What is the exercise price of the new MaxCyte (MXCT) stock options?

The stock options granted to Yasir B. Al-Wakeel have an exercise price of $1.13 per share. They cover 49,579 shares of MaxCyte Common Stock and were issued as part of his annual non-employee director equity compensation grant.

When do Yasir B. Al-Wakeel’s MaxCyte (MXCT) RSUs and options vest?

The shares underlying the annual equity grant vest on June 17, 2027, subject to Yasir B. Al-Wakeel’s continuous service as a director. Both the restricted stock units and related option grant follow MaxCyte’s Equity Grant Policy for non-employee directors.

How many MaxCyte (MXCT) shares does Yasir B. Al-Wakeel hold after this grant?

After receiving 30,421 restricted stock units, Yasir B. Al-Wakeel directly holds 80,998 shares of MaxCyte Common Stock. He also holds stock options over 49,579 additional shares, which are exercisable at an exercise price of $1.13 per share.

Is Yasir B. Al-Wakeel’s MaxCyte (MXCT) Form 4 a market purchase or a compensation grant?

The Form 4 reflects compensation grants, not a market purchase. It reports 30,421 restricted stock units and options for 49,579 shares awarded at no cost under MaxCyte’s Equity Grant Policy for non-employee directors, contingent on continued board service.